DRMAW
Income statement / Annual
Last year (2024), Dermata Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Dermata Therapeutics, Inc.'s net income was -$12.29 B.
See Dermata Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$322.00
|
$1,355.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$322.00
|
-$1,355.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$8.20 B
|
$4.07 M
|
$5.65 M
|
$3.46 M
|
$1.61 M
|
$2.62 M
|
| General & Administrative Expenses |
$4.31 B
|
$3.97 M
|
$4.02 M
|
$4.40 M
|
$1.57 M
|
$1.85 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$4.31 B
|
$3.97 M
|
$4.02 M
|
$4.40 M
|
$1.57 M
|
$1.85 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$12.51 B
|
$8.04 M
|
$9.67 M
|
$7.86 M
|
$3.17 M
|
$4.47 M
|
| Cost And Expenses |
$0.00
|
$8.04 M
|
$9.67 M
|
$7.86 M
|
$3.17 M
|
$4.47 M
|
| Interest Income |
$225.78 M
|
$247,216.00
|
$63,573.00
|
$45.61
|
$197.27
|
$250.75
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$45,613.00
|
$197,269.00
|
$250,748.00
|
| Depreciation & Amortization |
$0.00
|
$8.04 M
|
$9.67 M
|
$322.00
|
$322.00
|
$1,355.00
|
| EBITDA |
-$12.51 B |
$247,216.00 |
$0.00 |
-$7.86 M |
-$3.17 M |
-$4.47 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$225.78 M
|
$247,216.00
|
$63,573.00
|
-$45,613.00
|
-$63,677.00
|
-$250,748.00
|
| Income Before Tax |
-$12.29 B
|
-$7.79 M
|
-$9.61 M
|
-$7.90 M
|
-$3.24 M
|
-$4.72 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$9,674.49
|
$45,613.00
|
$197,269.00
|
$250,748.00
|
| Net Income |
-$12.29 B
|
-$7.79 M
|
-$9.61 M
|
-$7.95 M
|
-$3.43 M
|
-$4.97 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-8032.22 |
-40.18 |
-13.92 |
-15.27 |
-6.6 |
-9.55 |
| EPS Diluted |
-8032.22 |
-39.98 |
-13.92 |
-15.27 |
-6.6 |
-9.55 |
| Weighted Average Shares Out |
$1.53 M
|
$194,000.00
|
$690,666.00
|
$520,539.00
|
$520,539.00
|
$520,539.00
|
| Weighted Average Shares Out Diluted |
$1.53 M
|
$194,960.00
|
$690,666.00
|
$520,539.00
|
$520,539.00
|
$520,539.00
|
| Link |
|
|
|
|
|
|
